Hepatic veno-occlusive disease complicated with extreme hyperammonaemia (920 µmol/L) treated with defibrotide, lactulose, rifampin and haemodialysis.

Adult intensive care Cancer intervention Liver disease Oncology

Journal

BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291

Informations de publication

Date de publication:
21 Mar 2024
Historique:
medline: 22 3 2024
pubmed: 22 3 2024
entrez: 21 3 2024
Statut: epublish

Résumé

Hepatic veno-occlusive disease (VOD)/sinusoidal obstructive syndrome (SOS) is a severe complication that can occur following haematopoietic stem cell transplant (HSCT) with high-intensity conditioning chemotherapy regimens. Severe VOD/SOS, often characterised by multiorgan failure, is associated with a high mortality rate. This case report details the complex clinical course of a male patient in his mid-20s, recently diagnosed with B cell acute lymphoblastic leukaemia, who underwent allogeneic HSCT. Based on the 2023 European Society for Blood and Marrow Transplantation (EBMT) criteria, the patient developed very severe VOD/SOS, prompting immediate treatment with defibrotide. Unexpectedly, he developed profound hyperammonaemia exceeding 900 µmol/L, leading to encephalopathy and cerebral oedema. Despite aggressive interventions including defibrotide, lactulose, rifampin and haemodialysis, the patient passed away due to cerebral oedema and pulseless electrical activity arrest. We theorise the hyperammonaemia is disproportionate to his hepatic dysfunction and is possibly secondary to an acquired defect of the urea synthesis consistent with idiopathic hyperammonaemia, a rare complication in patients receiving intense conditioning chemotherapy.

Identifiants

pubmed: 38514165
pii: 17/3/e258876
doi: 10.1136/bcr-2023-258876
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Maciej Kabat (M)

Internal Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA maciej.kabat@hmhn.org.

Sarvarinder Gill (S)

Hematology and Oncology, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA.

Kevin Kim (K)

Pulmonary and Critical Care Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA.

Karan Omidvari (K)

Pulmonary and Critical Care Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA.

Robert Lee (R)

Pulmonary and Critical Care Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA.

Classifications MeSH